Galderma Announces Exclusive Agreement with Sofregen to Develop the Next Generation of Filler Biostimulators Using Silk-Based Technology | Business

LAUSANNE, Switzerland & FRAMINGHAM, Massachusetts – (BUSINESS WIRE) – Sep 23, 2021–

Galderma, the world’s largest independent dermatology company, and Sofregen Medical, Inc., a medical device company pioneering the use of silk proteins for tissue building and regeneration, today announced that they have signed a co-development and acquisition option agreement.

This collaboration will further expand Galderma’s capabilities based on decades of science-based aesthetic innovation and a unique heritage in the field of biostimulators and hyaluronic acid (HA) fillers. The new platform harnesses the unique power of silk protein to enable immediate volume restoration and provide structure that facilitates the generation of new tissue.

“At Galderma, we are committed to advancing dermatology through constant innovation and joining forces with other pioneers in the industry. The combination of Galderma’s capabilities and scale with Sofregen’s new silk platform represents a turning point for the aesthetics market through the development of a new category of biostimulator filler products designed to have a impact on healthcare professionals and their patients.

BALDO SCASSELLATI SFORZOLINI

GLOBAL HEAD OF RESEARCH & DEVELOPMENT

GALDERMA

Sofregen’s pioneering silk technology combines silk protein with an HA carrier. Of natural origin, silk has been shown to have unique properties for tissue support and regeneration, making it particularly suitable for cosmetic facial procedures.

“Galderma is a global leader in dermatology, with decades of experience in cutting edge innovation in facial aesthetics and we are delighted to have them as a partner. This agreement underscores Sofregen’s commitment to advancing silk science and will accelerate our ability to develop the next generation of biostimulant fillers with a recognized leader in this field.

JONATHAN T. HARTMANN

CHIEF EXECUTIVE OFFICER

SOFREGEN

Under the agreement, the companies will carry out specific co-development activities related to a portfolio of new silk-based biostimulatory fillers, demonstrating Galderma’s commitment to providing the market with scientific innovations. Galderma will also have an exclusive option to acquire Silk Voice ® ​​from Sofregen as well as assets related to its beauty business. This would give Galderma all the rights to the products co-developed by the parties, as well as the ownership of Sofregen’s silk technology platform in the aesthetic and dermatological field.

Galderma and Sofregen plan to launch development programs for all products imminently, with the two companies looking to start the collaboration and bring the products to market as quickly as possible.

About Sofregen’s Silk technology platform

Sofregen silk biostimulator filler consists of purified silk protein sponge particles mixed with cross-linked HA. The silk particles act as a scaffold and facilitate cell infiltration; over time, the silk will be enzymatically degraded, replaced by newly generated fabric. Preclinical studies show that when a suspension of these particles is injected through a small gauge needle, it works to facilitate long-lasting cell growth and collagen production, while slowly bioabsorbing over time. For more information: www.sofregen.com.

About Galderma

Galderma is the world’s largest independent dermatology company with operations in approximately 100 countries. Since our inception in 1981, we have been driven by total dedication to dermatology. We offer an innovative and scientific portfolio of sophisticated brands and services in the fields of aesthetics, consumer care and prescription medicine. Focused on the needs of consumers and patients, we work in partnership with healthcare professionals to ensure superior results. Because we understand that the skin we are in shapes our life stories, we advance dermatology for every skin story. For more information: www.galderma.com.

About Sofregen Medical

Sofregen is a pioneer in soft tissue engineering with an advanced platform based on silk protein, also known as fibroin, which has demonstrated its unique properties for tissue support and regeneration. Sofregen’s Silk platform is carefully designed to match soft tissue biomechanics for immediate swelling and long-term tissue replacement.

See the source version on businesswire.com: https://www.businesswire.com/news/home/20210922005995/en/

CONTACT: GaldermaChristian Marcoux, M.Sc.

Head of communications

[email protected]

+41 76 315 26 50 Shannon Iwaniuk

Global Communications, United States

[email protected] Schieffer

Anzu Partners

[email protected]équenceners.com

KEYWORD: MASSACHUSETTS EUROPE SWITZERLAND UNITED STATES NORTH AMERICA

INDUSTRY KEYWORD: SCIENCE OTHER SCIENCE BIOTECHNOLOGY MEDICAL SUPPLIES MEDICAL HEALTH COSMETIC DEVICES RETAIL TRADE

SOURCE: Galderma

Copyright Business Wire 2021.

PUB: 23/09/2021 1:00 a.m. / DISC: 23/09/2021 1:02 a.m.

http://www.businesswire.com/news/home/20210922005995/en

Copyright Business Wire 2021.

Comments are closed.